Outperforming Traditional Staging: A Novel Nomogram for HR-Positive Breast Cancer
Chaoxing Liu,1– 3,* Jiabin Ding,1– 3,* Jinbiao Xu,1– 3,* Chen Fang,1– 3 GuoHua Zhang,2 Chao Shi,1,3 Feng Qiu1,3 1Department of Oncology, Gaoxin Branch of the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People’s Republic of China; 2Nanchang Key Laborat...
Saved in:
| Main Authors: | Liu C, Ding J, Xu J, Fang C, Zhang G, Shi C, Qiu F |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-02-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/outperforming-traditional-staging-a-novel-nomogram-for-hr-positive-bre-peer-reviewed-fulltext-article-TCRM |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Nomograms for predicting recurrence of HER2‐positive breast cancer with different HR status based on ultrasound and clinicopathological characteristics
by: Xudong Zhang, et al.
Published: (2024-09-01) -
A prediction model for predicting relapsed-free survival of early-stage invasive breast cancer patients with hormone receptor positive based on Ki67, HER2 and TOP2A
by: Dawei Yuan, et al.
Published: (2025-04-01) -
Risk Stratification of Early Breast Cancer (HR +/HER 2–) by CanAssist Breast and Its Corelation with Other Online Prognostic Tools: Experience from a Single Center
by: Ajay Bapna, et al. -
High chromosomal instability is associated with higher 10‐year risks of recurrence for hormone receptor‐positive, human epidermal growth factor receptor 2‐negative breast cancer patients: clinical evidence from a large‐scale, multiple‐site, retrospective study
by: Yu‐Yang Liao, et al.
Published: (2024-11-01) -
Combination chemotherapy and hormone therapy in patients with hormone receptor positive and HER2 negative metastatic breast cancer
by: Kripa Bajaj, et al.
Published: (2025-08-01)